Sanofi Company Profile (NYSE:SNY)

About Sanofi (NYSE:SNY)

Sanofi logoSanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: N/A
  • Symbol: NYSE:SNY
  • CUSIP: N/A
  • Web: www.sanofi.com
Capitalization:
  • Market Cap: $121.03 billion
  • Outstanding Shares: 2,511,508,000
Average Prices:
  • 50 Day Moving Avg: $47.84
  • 200 Day Moving Avg: $46.41
  • 52 Week Range: $36.81 - $50.24
P/E:
  • Trailing P/E Ratio: 11.43
  • Foreward P/E Ratio: 14.09
  • P/E Growth: 1.92
Sales & Book Value:
  • Annual Revenue: $42.69 billion
  • Price / Sales: 2.84
  • Book Value: $26.99 per share
  • Price / Book: 1.79
Dividend:
  • Annual Dividend: $1.10
  • Dividend Yield: 3.4%
Profitability:
  • EBIDTA: $12.81 billion
  • Net Margins: 25.89%
  • Return on Equity: 25.34%
  • Return on Assets: 14.17%
Debt:
  • Debt-to-Equity Ratio: 0.26%
  • Current Ratio: 1.59%
  • Quick Ratio: 1.16%
Misc:
  • Average Volume: 1.54 million shs.
  • Beta: 0.88
  • Short Ratio: 1.35
 

Frequently Asked Questions for Sanofi (NYSE:SNY)

What is Sanofi's stock symbol?

Sanofi trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNY."

How often does Sanofi pay dividends? What is the dividend yield for Sanofi?

Sanofi declared an annual dividend on Friday, February 17th. Shareholders of record on Monday, May 15th will be paid a dividend of $1.5771 per share on Wednesday, June 7th. This represents a dividend yield of 3.65%. The ex-dividend date of this dividend is Thursday, May 11th. This is an increase from Sanofi's previous annual dividend of $1.10. View Sanofi's Dividend History.

How were Sanofi's earnings last quarter?

Sanofi (NYSE:SNY) posted its quarterly earnings results on Monday, July, 31st. The company reported $0.74 earnings per share for the quarter, meeting the Zacks' consensus estimate of $0.74. The firm had revenue of $8.66 billion for the quarter, compared to the consensus estimate of $8.71 billion. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The firm's revenue was down 2.3% on a year-over-year basis. View Sanofi's Earnings History.

When will Sanofi make its next earnings announcement?

Sanofi is scheduled to release their next quarterly earnings announcement on Friday, October, 27th 2017. View Earnings Estimates for Sanofi.

Where is Sanofi's stock going? Where will Sanofi's stock price be in 2017?

14 equities research analysts have issued 12 month price targets for Sanofi's stock. Their forecasts range from $52.00 to $55.00. On average, they expect Sanofi's stock price to reach $53.50 in the next year. View Analyst Ratings for Sanofi.

Who are some of Sanofi's key competitors?

Who are Sanofi's key executives?

Sanofi's management team includes the folowing people:

  • Serge Weinberg, Independent Chairman of the Board
  • Olivier Brandicourt, Chairman of the Executive Committee, Chief Executive Officer, Director
  • Jerome Contamine, Executive Vice President, Chief Financial Officer, Member of the Executive Committee and the Senior Leadership Team
  • Karen Marie Linehan, Executive Vice President, Legal Affairs and General Counsel, Member of the Executive Committee and the Senior Leadership Team
  • Olivier Charmeil, Executive Vice President and General Manager, General Medicines & Emerging Markets, Member of the Executive Committee and the Senior Leadership Team
  • Peter Guenter, Executive Vice President and General Manager, Diabetes & Cardiovascular, Member of the Executive Committee and the Senior Leadership Team
  • Carsten Hellmann, Executive Vice President and General Manager of Merial, Member of the Executive Committee and the Senior Leadership Team
  • David Loew, Executive Vice President and General Manager of Sanofi Pasteur, Member of the Executive Committee and the Senior Leadership Team
  • David P. Meeker M.D., Executive Vice President and General Manager of Sanofi Genzyme, Member of the Executive Committee and the Senior Leadership Team
  • Roberto Pucci, Executive Vice President, Human Resources, Member of the Executive Committee and the Senior Leadership Team

Who owns Sanofi stock?

Sanofi's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Dodge & Cox (2.50%), Franklin Resources Inc. (0.83%), Fisher Asset Management LLC (0.54%), Boston Partners (0.32%), Hotchkis & Wiley Capital Management LLC (0.23%) and FMR LLC (0.21%). View Institutional Ownership Trends for Sanofi.

Who sold Sanofi stock? Who is selling Sanofi stock?

Sanofi's stock was sold by a variety of institutional investors in the last quarter, including Dodge & Cox, Hotchkis & Wiley Capital Management LLC, Wells Fargo & Company MN, Federated Investors Inc. PA, Boston Partners, Macquarie Group Ltd., Northern Trust Corp and Tekla Capital Management LLC. View Insider Buying and Selling for Sanofi.

Who bought Sanofi stock? Who is buying Sanofi stock?

Sanofi's stock was acquired by a variety of institutional investors in the last quarter, including Southpoint Capital Advisors LP, Fisher Asset Management LLC, BlackRock Inc., Janus Henderson Group PLC, FMR LLC, Harbour Capital Advisors LLC, Aperio Group LLC and Schafer Cullen Capital Management Inc.. View Insider Buying and Selling for Sanofi.

How do I buy Sanofi stock?

Shares of Sanofi can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sanofi's stock price today?

One share of Sanofi stock can currently be purchased for approximately $48.19.


MarketBeat Community Rating for Sanofi (NYSE SNY)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  212 (Vote Outperform)
Underperform Votes:  269 (Vote Underperform)
Total Votes:  481
MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sanofi (NYSE:SNY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 8 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.14)
Consensus Price Target: $53.50 (11.02% upside)

Analysts' Ratings History for Sanofi (NYSE:SNY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/1/2017Cowen and CompanyReiterated RatingMarket Perform$46.00 -> $52.00LowView Rating Details
6/9/2017ArgusBoost Price TargetBuy$50.00 -> $55.00LowView Rating Details
5/11/2017Berenberg BankDowngradeBuy -> HoldLowView Rating Details
4/20/2017J P Morgan Chase & CoReiterated RatingNeutralMediumView Rating Details
4/7/2017HSBC Holdings plcDowngradeHold -> ReduceLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageHold -> HoldLowView Rating Details
3/7/2017Barclays PLCInitiated CoverageUnderweightN/AView Rating Details
2/9/2017NatixisUpgradeNeutral -> BuyN/AView Rating Details
1/10/2017Leerink SwannReiterated RatingOutperformN/AView Rating Details
1/8/2017Goldman Sachs Group, Inc. (The)Reiterated RatingHoldN/AView Rating Details
11/29/2016Morgan StanleyUpgradeEqual Weight -> OverweightN/AView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageNeutralN/AView Rating Details
9/14/2016Jefferies Group LLCReiterated RatingHoldN/AView Rating Details
9/13/2016BNP ParibasUpgradeUnderperform -> NeutralN/AView Rating Details
6/28/2016Citigroup Inc.Reiterated RatingNeutralN/AView Rating Details
5/3/2016Bank of America CorporationReiterated RatingBuy$58.00N/AView Rating Details
4/12/2016Chardan CapitalReiterated RatingBuyN/AView Rating Details
2/10/2016Sanford C. BernsteinLower Price TargetMarket-Perform$52.00 -> $45.00N/AView Rating Details
12/16/2015Oddo SecuritiesDowngradeReduceN/AView Rating Details
11/9/2015Bryan, Garnier & CoReiterated RatingBuy -> NeutralN/AView Rating Details
9/16/2015Sarasin & PartnersUpgradeBuyN/AView Rating Details
(Data available from 8/20/2015 forward)

Earnings

Earnings History for Sanofi (NYSE:SNY)
Earnings by Quarter for Sanofi (NYSE:SNY)
Earnings History by Quarter for Sanofi (NYSE SNY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/27/2017        
7/31/20176/30/2017$0.74$0.74$8.71 billion$8.66 billionViewN/AView Earnings Details
4/28/20173/31/2017$0.73$0.76$8.40 billion$8.65 billionViewN/AView Earnings Details
2/8/2017Q416$0.66$0.67$9.87 billion$8.88 billionViewN/AView Earnings Details
10/29/2015Q315$0.88$0.89$10.97 billion$10.67 billionViewN/AView Earnings Details
4/30/2015Q115$0.61$0.73$9.21 billion$9.78 billionViewN/AView Earnings Details
2/5/2015Q4$0.89$0.79$11.34 billion$10.39 billionViewN/AView Earnings Details
7/31/2014Q2$0.79$0.72$11.19 billion$10.82 billionViewN/AView Earnings Details
4/29/2014Q114$0.84$0.81$11.19 billion$10.88 billionViewN/AView Earnings Details
2/6/2014Q4$0.88$0.93ViewN/AView Earnings Details
10/30/2013$1.01$0.93ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sanofi (NYSE:SNY)
2017 EPS Consensus Estimate: $3.21
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.75$0.78$0.77
Q2 20171$0.74$0.74$0.74
Q3 20171$0.90$0.90$0.90
Q4 20171$0.80$0.80$0.80
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Sanofi (NYSE:SNY)
Most Recent Dividend:6/7/2017
Annual Dividend:$1.10
Dividend Yield:2.28%
Dividend Growth:-2.50% (3 Year Average)
Payout Ratio:28.06% (Trailing 12 Months of Earnings)
33.74% (Based on This Year's Estimates)
32.16% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Sanofi (NYSE:SNY)

Dividend History by Quarter for Sanofi (NYSE SNY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/17/2017annual$1.583.65%5/11/20175/15/20176/7/2017
2/22/2016Annual$1.105/5/20165/9/20166/1/2016
2/26/2015special$1.623.91%5/6/20155/8/20156/2/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Sanofi (NYSE:SNY)
Insider Ownership Percentage: 1.00%
Institutional Ownership Percentage: 9.90%
Insider Trades by Quarter for Sanofi (NYSE:SNY)
Institutional Ownership by Quarter for Sanofi (NYSE:SNY)
Insider Trades by Quarter for Sanofi (NYSE:SNY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/9/2014SanofiMajor ShareholderBuy195,000$308.27$60,112,650.00View SEC Filing  
7/8/2014SanofiMajor ShareholderBuy153,000$311.67$47,685,510.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Sanofi (NYSE:SNY)
Latest Headlines for Sanofi (NYSE:SNY)
Source:
DateHeadline
finance.yahoo.com logoSanofi Genzyme Continues Driving Revenue Growth in 2Q17
finance.yahoo.com - August 18 at 7:21 AM
finance.yahoo.com logoEuropean Pharma Companies Slip on MS Pricing Probe
finance.yahoo.com - August 18 at 7:21 AM
cnbc.com logoSen. Grassley says Mylan's $465 million Epi-Pen settlement 'shortchanges' taxpayers
www.cnbc.com - August 17 at 6:17 PM
latimes.com logoEpiPen maker settles: It'll pay less than what it got by allegedly overcharging
www.latimes.com - August 17 at 5:27 PM
finance.yahoo.com logoETFs with exposure to Sanofi : August 16, 2017
finance.yahoo.com - August 17 at 7:46 AM
finance.yahoo.com logoSanofi’s Revenue Growth in 2Q17
finance.yahoo.com - August 17 at 7:46 AM
americanbankingnews.com logoSanofi (SNY) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - August 15 at 10:46 PM
seekingalpha.com logoSanofi's Zika Standoff: Bad Medicine? - Seeking Alpha
seekingalpha.com - August 11 at 8:40 AM
streetinsider.com logoSanofi (SNY) Sues to Defend its Patent Rights on Lantus - StreetInsider.com
www.streetinsider.com - August 9 at 7:40 AM
streetinsider.com logoSanofi (SNY) Sues to Defend its Patent Rights on Lantus - StreetInsider.com
www.streetinsider.com - August 9 at 7:40 AM
seekingalpha.com logoDupixent Asthma Data Could Seal A Second Blockbuster Market - Seeking Alpha
seekingalpha.com - August 9 at 7:40 AM
seekingalpha.com logoDupixent Asthma Data Could Seal A Second Blockbuster Market - Seeking Alpha
seekingalpha.com - August 9 at 7:40 AM
finance.yahoo.com logoThis Week's Pharma, Energy IPOs
finance.yahoo.com - August 8 at 6:59 AM
americanbankingnews.com logoSanofi (SNY) Upgraded by BidaskClub to Hold
www.americanbankingnews.com - August 5 at 5:30 PM
seekingalpha.com logoRegeneron to terminate antibody discovery partnership with Sanofi at year-end - Seeking Alpha
seekingalpha.com - August 4 at 8:22 AM
seekingalpha.com logoSanofi Q2/2017: Mixed Signals - Seeking Alpha
seekingalpha.com - August 4 at 8:22 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for Sanofi Decreased by Leerink Swann (SNY)
www.americanbankingnews.com - August 4 at 7:02 AM
zacks.com logoSanofi (SNY) Q2 Earnings In Line, Sales Lag,'17 View Raised
www.zacks.com - August 2 at 2:09 AM
barrons.com logoRegeneron: Time to Sell? - Barron's
www.barrons.com - August 1 at 4:04 PM
finance.yahoo.com logoPrince Edward Island includes LEMTRADA® (alemtuzumab) on provincial drug program for eligible patients
finance.yahoo.com - August 1 at 4:04 PM
finance.yahoo.com logoWhy Sanofi Earnings Spooked Regeneron Shares To A 6-Week Low
finance.yahoo.com - August 1 at 4:04 PM
finance.yahoo.com logoRegeneron: Time to Sell?
finance.yahoo.com - August 1 at 4:04 PM
americanbankingnews.com logoSanofi (NYSE:SNY) Releases Earnings Results, Meets Estimates
www.americanbankingnews.com - August 1 at 11:57 AM
barrons.com logoWhy Regeneron is Slumping - Barron's
www.barrons.com - August 1 at 6:27 AM
nasdaq.com logoEarnings Reaction History: Sanofi-Aventis, 37.5% Follow-Through Indicator, 1.9% Sensitive - Nasdaq
www.nasdaq.com - August 1 at 6:27 AM
seekingalpha.com logoSanofi Q2 revenues up 4%; non-GAAP EPS up 3%; shares ahead 2% premarket - Seeking Alpha
seekingalpha.com - August 1 at 6:27 AM
feeds.benzinga.com logoSanofi: Online Availability of Sanofi Group's Half-Year Financial Report for 2017
feeds.benzinga.com - July 31 at 3:19 PM
seekingalpha.com logoSanofi reports Q2 results
seekingalpha.com - July 31 at 6:28 AM
finance.yahoo.com logoSanofi raises outlook after strong Q2 sales growth
finance.yahoo.com - July 31 at 4:39 AM
finance.yahoo.com logoSanofi's CFO Says Growth in EM Has Been Steady
finance.yahoo.com - July 31 at 4:39 AM
finance.yahoo.com logoSanofi Lifts 2017 Earnings Guidance as Consumer Healthcare Surge Boosts Q2 Earnings
finance.yahoo.com - July 31 at 4:39 AM
feeds.benzinga.com logoZealand reports royalty revenue for the second quarter of 2017
feeds.benzinga.com - July 31 at 3:26 AM
streetinsider.com logoUPDATE: Sanofi (SNY) Generic Unit Said to Draw Advent, Cinven and Bain Duo; Sale Likely to Kick Off Post-Summer ... - StreetInsider.com
www.streetinsider.com - July 29 at 7:25 AM
americanbankingnews.com logoSanofi (SNY) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - July 27 at 3:45 PM
barrons.com logoEli Lilly: The Competition is Just Too Darn Intense! - Barron's
www.barrons.com - July 27 at 7:39 AM
barrons.com logoEli Lilly: The Competition is Just Too Darn Intense! - Barron's
www.barrons.com - July 27 at 7:39 AM
americanbankingnews.com logo Brokerages Anticipate Sanofi (NYSE:SNY) Will Announce Quarterly Sales of $9.98 Billion
www.americanbankingnews.com - July 23 at 11:52 AM
streetinsider.com logoSanofi (SNY) and Regeneron (REGN) Receive Positive CHMP Opinion for Dupixent to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
www.streetinsider.com - July 23 at 8:15 AM
finance.yahoo.com logoRegeneron and Sanofi Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
finance.yahoo.com - July 23 at 8:15 AM
finance.yahoo.com logoSanofi Receives CHMP Positive Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
finance.yahoo.com - July 23 at 8:15 AM
nasdaq.com logoMerck's Biosimilar Insulin Gets Tentative FDA Approval - Nasdaq
www.nasdaq.com - July 22 at 8:59 AM
nasdaq.com logoMerck's Biosimilar Insulin Gets Tentative FDA Approval - Nasdaq
www.nasdaq.com - July 22 at 8:59 AM
streetinsider.com logoSanofi (SNY) and Regeneron (REGN) Receive Positive CHMP ... - StreetInsider.com
www.streetinsider.com - July 22 at 8:59 AM
streetinsider.com logoSanofi (SNY) and Regeneron (REGN) Receive Positive CHMP ... - StreetInsider.com
www.streetinsider.com - July 22 at 8:59 AM
americanbankingnews.com logoSanofi (SNY) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - July 21 at 10:40 PM
americanbankingnews.com logoSanofi (SNY) Expected to Announce Earnings of $0.75 Per Share
www.americanbankingnews.com - July 21 at 8:08 AM
nasdaq.com logoFDA tentatively approves Merck's copycat of Sanofi's Lantus - Nasdaq
www.nasdaq.com - July 21 at 7:16 AM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE- Sears, Nike, Sarepta ... - Nasdaq - Nasdaq
www.nasdaq.com - July 21 at 7:16 AM
seekingalpha.com logoAblynx and Sanofi team up to develop Nanobody-based therapeutics for inflammatory diseases; Sanofi up 2% premarket - Seeking Alpha
seekingalpha.com - July 20 at 7:55 AM
streetinsider.com logoSanofi Pasteur (SNY) Ships First Influenza Vaccine Doses for 2017-2018 Season
www.streetinsider.com - July 19 at 1:49 AM

Social

Chart

Sanofi (SNY) Chart for Sunday, August, 20, 2017

This page was last updated on 8/20/2017 by MarketBeat.com Staff